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Abstract 
The adaptive immune system is a natural diagnostic and therapeutic. It recognizes threats earlier than 
clinical symptoms manifest and neutralizes antigen with exquisite specificity. Recognition specificity and 
broad reactivity is enabled via adaptive B- and T-cell receptors: the immune receptor repertoire. The human 
immune system, however, is not omnipotent. Our natural defense system sometimes loses the battle to 
parasites and microbes and even turns against us in the case of cancer and (autoimmune) inflammatory 
disease. A long-standing dream of immunoengineers has been, therefore, to mechanistically understand 
how the immune system “sees”, “reacts” and “remembers” (auto)antigens. Only very recently, experimental 
and computational methods have achieved sufficient quantitative resolution to start querying and 
engineering adaptive immunity with great precision. In specific, these innovations have been applied with 
the greatest fervency and success in immunotherapy, autoimmunity and vaccine design. The work here 
highlights advances, challenges and future directions of quantitative approaches which seek to advance the 
fundamental understanding of immunological phenomena, and reverse engineer the immune system to 
produce auspicious biopharmaceutical drugs and immunodiagnostics. Our review indicates that the merger 
of fundamental immunology, computational immunology and (digital) biotechnology minimizes black box 
engineering, thereby advancing both immunological knowledge and as well immunoengineering 
methodologies.  
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Introduction 
 
Advancing immunology through engineering innovations 
Theodore von Kármán, the great 20th century aerospace engineer, famously stated that scientists study the 
world as it is, while engineers create the world that has never been1. Fundamental questions in science often 
could only be addressed after the development of pioneering engineering solutions. Recent examples such 
as the development of Taq polymerase, GFP and its derivatives, CRISPR/Cas9, high-throughput 
sequencing and proteomics have enabled researchers to answer countless fundamental questions in science, 
otherwise impossible to approach.  
 
Advances in developing a quantitative understanding of the adaptive immune repertoire has been often 
brought about by biotechnology tools that have made possible performing high-throughput work. 
Quantitative tools have allowed us to expose enormous quantities of immune receptor sequences and their 
characteristics2–15. Emergent tools in high-throughput and synthetic biology have enabled technologies for 
seamless integration of gene constructs,  gene circuit engineering, DNA assembly, and gene synthesis16,17. 
While many of these transformative ideas originate with the intention of solving problems pertinent to the 
adaptive immune repertoires, it is also true that the development of new quantitative and synthetic tools is 
a pervasive pursuit across many fields. The merger of synthetic and quantitative tools opens the space for 
not only the analysis, redesign and optimization of existing T cell receptors (TCRs) and antibodies, but also 
the de novo design of proteins heretofore unknown to nature. Moreover, we perceive the utility of several 
computational, genomics, proteomics and biotechnology tools that have not been developed with the 
immune repertoire in mind but are compelling candidate techniques to incorporate into the quantitative 
immunoengineering toolset for the purpose of the quantitative analysis and engineering of adaptive immune 
receptors. 
 
Here we review and retrace works operating at the interface of immunoengineering and fundamental 
immunology that have solved fundamental questions in high-throughput adaptive immune repertoires and 
have furthered the promise of precision engineered immunotherapies and vaccine design.  
 
Adaptive immune receptors are natural diagnostics and therapeutics  
B and T cells together make up the adaptive immune system that detects and fights infection and disease 
with specificity. The power of adaptive immune cell populations is showcased by their dysregulation. 
Autoimmunity describes a class of diseases, such as celiac disease18,19 or Type 1 Diabetes20,21 in which 
immune cells turn against the host with disastrous consequences. The protein receptors that confer both 
such incredible protective and destructive capacity are B- and T-cell receptors, immune receptors. In their 
soluble form, secreted by plasma cells, B-cell receptors (BCRs) are called antibodies. In this review, the 
terms BCR and antibody are used interchangeably if not specified otherwise. 
Immune repertoires are a natural diagnostics; they respond to a pathogen prior to the emergence of clinical 
symptoms22. This is the premise of most immunodiagnostic tests that use adaptive immune system 
dynamics as biomarkers23. Consequently, a long-standing goal has been to perform repertoire-based 
diagnostics of immune state by minimally invasive blood repertoire sequencing. The underlying assumption 
of repertoire-based immunodiagnostics is that a disease induces, across affected individuals, disease-
associated receptor sequence (motifs) that function as disease biomarkers24. Recently, Emerson and 
colleagues were able to discriminate between cytomegalovirus (CMV) positive and negative individuals 
based solely on the presence of CMV-associated TCR sequences25.  
Immune receptors bind (auto)antigens with specificity leading to the neutralization through antibodies or 
elimination of (auto)antigens through (T cells). Upon activation, the adaptive immune system clears the 
eliciting antigen from the body thereby behaving as a bona fide therapeutic. In 1986, the first monoclonal 
antibody was FDA-approved as a treatment in kidney transplantation26. As of February 2019, 113 
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monoclonal antibodies have been approved by the US Food and Drug Administration (FDA) and/or 
European Medicines Agency, and hundreds more are being actively tested in clinical trials27. Antibodies 
feature among blockbuster drugs, highlighting the importance of immunotherapy for public health27–29. 
Complementarily, the first chimeric antigen receptor (CAR) T cells therapeutics have been FDA-approved 
in 2017 for the treatment of B-cell malignancies.  
In summary, antibody and T-cell receptors are important as diagnostics and therapeutics. Therefore, 
enormous efforts are currently undertaken to develop tools and platforms that enable (digital) 
immunoengineering at a large, quantitative scale30–32. 
 
Engineering the vast immune receptor sequence space requires quantitative approaches 
Directed, rule and knowledge-driven B-and T-cell engineering depends on the understanding of immune 
receptor biology, the structure of the antigenome and the potential interaction space that links immune 
receptors to antigens. 
 
Since the first publications on high-throughput immune repertoire sequencing33–35, the diversity of immune 
receptor repertoires has been described in extensive detail by sophisticated experimental and computational 
approaches as also reviewed by others2,3,10,36–40. For example, the number of immune receptors stored in the 
iReceptor database, a searchable public portal for immune repertoire studies, recently exceeded  1 billion7. 
On the single individual level, a new frontier in sequencing depth has been recently established with 107  
sequencing reads per individual closing in on the number of lymphocytes in the blood (108)41. Similarly, 
antigen landscapes have been investigated using both mass spectrometry and display technologies (e.g., 
phage display, peptide and protein arrays)42,43. These investigations have led to large epitope databases such 
as the Immune Epitope Database (IEDB) that include more than validated 130,000 peptide epitopes43. Thus, 
the charted landscape of immune receptor sequence and epitope diversity is constantly expanding. 
 
Despite ever growing data resources, the ability to link immune receptor and antigen sequence, at high-
throughput, has only recently begun to be investigated. The complexity of immune receptor diversity, the 
antigenome and their interaction space, requires experimental and computational analytical approaches to 
identify and detect engineerable interaction patterns and rules. In this review, we define quantitative 
immunoengineering as the set of high-throughput, high-precision genomic, proteomic, computational and 
biotechnology tools that have jointly created an unprecedented opportunity to repair, (re-)create and 
improve human adaptive immunity. 
Current approaches for immune repertoire analysis and immunoengineering 
 
Computational immunology and immunoinformatics of adaptive immunity 
Computational immunology is of crucial importance for understanding the complexity of adaptive 
immunity11. De novo immunoengineering of adaptive immunity requires (i) knowledge and replication of 
germline gene recombination, (ii) understanding of disease and antigen-specific patterns in immune 
repertoires, (iii) analysis of B-and T-cell population dynamics, and (iv) modeling of immune receptor 3D 
structure. In these four areas, remarkable computational progress has been made over the past years. We 
believe that the computational progress described here is needed to analyze ultra-large immune receptor 
(>107 clonal sequences) datasets with greater efficiency44. 
 
Immune repertoire in silico simulation and diversity 
The rules of V(D)J recombination shaping immune repertoire structure have been under intense 
investigation since the seminal paper by Mora and Walczak in 201045. Throughout a series of papers, the 
groups of Walczak and Mora have showed that V(D)J recombination in B and T cells may be modeled by 
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Hidden Markov models46 as well as Bayesian probabilistic methods47. These models of VDJ recombination, 
trained by repertoire sequencing data, have been applied to the investigation of: (i)  potential repertoire 
diversity and estimation of receptor sequence generation probabilities45,48,49, (ii) repertoire selection50–52, 
(iii) the phenomenon of naïve public clones and the identification of antigen-specific public clones47,53,54, 
(iv) and for the generation of nature-like immune repertoires47,55.  
 
Mora, Walczak and other groups found that the potential mouse and human naïve B- and T-cell diversity 
is at least 1014 48,49,56,57, respectively. Despite the immense repertoire diversity, we know of many instances 
of individuals sharing similar or identical public immune receptors with each other8,9,25,56,58–61. Functionally, 
these patterns are likely to be public markers of evolutionary memory, immunological memory and human 
leukocyte antigen (HLA), with the most highly correlated clusters strongly linked to common viral 
pathogens62,63. The authors showed that naïve public clones are well explained by power-law distributed 
VDJ recombination statistics. The computational tools IGoR64 (nucleotide level) and Olga (amino acid 
level)55 implement methods for estimation of VDJ recombination scenarios as well as generation of in 
immune receptor sequences given an germline gene sets and inferred recombination statistics. Using 
IGgoR, Briney and colleagues have showed that inferred VDJ recombination models differ across 
individuals. This suggests that the practice of using one general of VDJ recombination across all individuals 
might yield less accurate results8. This finding is in line with the emergence of personalized germline gene 
repertoires through the existence of immunoglobulin germline gene polymorphisms65–68. An increasing 
number of antibody polymorphisms67,69 warrants also the question of how repertoire variation on the 
germline gene level translates to the creation of  antigen-specific immune antibody repertoires65.  
 
Multiple reports have provided evidence for a power-law distribution of clonal diversity45,70–72. It has been 
previously suggested that power-law distributions arise in the presence of hidden unobserved variables, 
such as that of pathogens73. Complementarily, Desponds and colleagues showed that power-law distribution 
of lymphocyte clones can arise solely due to fitness fluctuations. In agreement with Schwab and 
colleagues73, Desponds and colleagues found that power-law distributions can result entirely from an 
exogenous environment with which the adaptive immune system interacts.  
 
Given the power-law nature of clonal frequency distributions (p), one can assume that they contain 
immunological information. In order to capture this information, clonal frequency distributions have to be 
converted to a common reference framework that is clone-independent. Clone-independence is important 
since there is little overlap across individuals (despite there being considerable numbers of public 
clones8,9,56). Such clonal independence was achieved with the help of prior work in mathematical ecology. 
Specifically, calculating the exponential of the Rényi entropy, called Hill-Diversity profiles,  
((∑ 𝑝$%&$'( ) ((*%), across an array of q-values yields a lower-dimensional vector that was shown to capture a 
large extent of the information contained in clonal frequency distributions70. Hill-diversity profiles capture 
the state of clonal expansion of any given immune repertoire and could discriminate mouse immunization, 
health, transplantation and cancer statuses, as well as lymphocyte populations56,70,74.  
 
While diversity profiles capture the information contained in the clonal frequency distribution, they do not 
capture sequence-dependent information. Two clonal repertoires may have identical clonal frequency 
distributions but may be composed of entirely different clonal sequences. Sequence-dependent information 
is captured by the sequence similarity landscape of immune repertoires53,63,75–77. Specifically, the similarity 
landscape of a repertoire may be determined by calculating the sequence distance matrix [Levenshtein 
distance] of an immune repertoire. Using this distance matrix, a network can be drawn wherein each clonal 
sequence is a node and each edge indicates an editdistance (number of changes to convert one nucleotide 
or amino acid sequence into another sequence) between clones. Such networks may be drawn for both B 
cells76,77 and T cells63. If calculated across several distance cut-offs, these networks may be used to compare 
distinct layers of repertoire similarity, which has offered unprecedented insight into the architecture of 
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repertoire similarity77. For example, Miho and colleagues found that these layers are correlated, suggesting 
that similarity in repertoires is organized according to underlying but, as of yet, unidentified rules. Another 
striking observation in  immune repertoires is that public clones are biased to higher frequency and seem 
to represent network hubs63,77 surrounded by private clones77. Finally, Priel and colleagues recently 
published a method for following network architecture of T-cell receptor repertoires over time as well as 
analyzing it via machine learning78.  
 
While inspecting the similarity relation landscape of a repertoire provides crucial insight into repertoire 
biology, computational demands for investigating repertoire similarity may become prohibitive for larger 
repertoires. Indeed, networks of repertoire sizes larger than 100,000 clones require either cloud services or 
parallelized computational frameworks on large-scale computing clusters as recently developed by Miho 
and colleagues77. By calculating networks of millions of clones, Miho and colleagues showed that the 
practice of inspecting a portion of a repertoire (subsampling) may be acceptable, depending on the number 
of public clones in the subsampled portion. In fact, random samples of up to 50% of the original repertoire-
maintained network properties similar to the originating repertoire. In this regard, network analysis and 
diversity profiles show similar robustness to undersampling70,77.  
 
Clonal frequency and the sequence similarity landscape contain complementary immunological 
information. In recent work, Arora and colleagues as well as Strauli and colleagues published mathematical 
frameworks allowing the merging of sequence and frequency information 79,80, however it remains 
undetermined how immunological information is distributed among frequency and sequence-based 
repertoire components81,82.  
 
In summary, we can now generate in silico immune repertoires and quantify repertoire diversity thanks to 
advances in probabilistic modeling, mathematical ecology and network theory.  
 
B-and T-cell pattern mining using machine and deep learning 
Immune receptor specificity is one of the hallmark features of adaptive immunity and encoded into the 
sequence of each immune receptor in motifs. An underlying assumption of pattern mining is that receptors 
that are specific for a given antigen, share similarity of certain motifs.  
 
Davis, Thomas and Laukens’ groups published seminal papers regarding T-cell receptors showing that 
prediction of TCR antigen specificity can be performed based on the TCR sequence alone with high 
accuracy (≈80%)24,83–85. The authors used distance-based classifiers (TCRDist24 and GLIPH83) and other 
sequence features such as complementarity-determining region 3 (CDR3) length and CDR3 
physicochemical properties84. Recently, Jokinen and colleagues published a method based on Gaussian 
processes (called TCRGP) that, in contrast to TCRDist24, does not assign a priori weights to CDR regions 
when predicting antigen specificity on the entire VDJ region86 improving on the performance of TCRDist 
by 6% percentage points (86% prediction accuracy). Distance-based clustering approaches for epitope-
specific clustering of immune receptors were formally benchmarked in reports from Meysman as well as 
Thakkar and colleagues that investigated different distance metrics and alignments for TCR-based 
clustering. These studies indicate that, at least for TCR-based analysis, distance-based measures are well 
suited for finding commonalities among epitope-specific TCRs, disease-associated TCRs and TCR across 
individuals (such as twins). However, simple distance-based measures render differentiation between short 
and long-range sequence interaction unfeasible.  Specifically, outlier sequences that are very dissimilar to 
the main sequence cluster but still bind to the same epitope are not captured by these distance-based 
classifiers. These outlier sequences remain a challenge for future research – both for supervised and 
unsupervised approaches87. As of yet, it remains unclear to what extent short and long-range interactions 
govern major histocompatibility complex (MHC)-TCR-antigen interaction. Recent data by Ostmeyer 
indicate that interaction of TCR and peptide is well-captured by short and continuous sequence stretches82. 
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For antibodies, there exist fewer approaches for sequence-based prediction of antigen specificity. 
Previously, two approaches have been published that involve deep learning of paratope and paratope-
epitope coupled prediction of antibody-antigen binding, respectively88,89.  Using the structural information 
from antibody-antigen complexes, Liberis and colleagues built a deep learning classifier based on 
convolutional and recurrent neural networks that incorporated both amino acid sequence and physico-
chemical property information. Using their deep learning classifier, they were able to predict paratope 
residues with an F1-score [a measure of prediction accuracy] of 0.69. Importantly the deep learning model 
also inferred well the binding frequency of each amino acid in a paratope. In a follow-up manuscript, the 
authors substituted the recurrent layer with convolutional layers specifically designed to cover longer range 
sequence interaction as well as a cross-modal-attention layer of antibody over the antigen residue features88. 
Interestingly, by incorporating antigen information into the paratope predictor, prediction results were only 
improved slightly. This may be due to the limited number of antibody-antigen complexes currently 
available (≈800)90. 
 
Greiff and colleagues used sequence motifs to predict sequence publicity of BCR and TCR clones91. 
Leveraging a gapped-k-mer SVM approach92, they found that there exist motifs that predict both in mouse 
and human, immune receptor publicity with 80% prediction accuracy. The classifier was tested to perform 
well across datasets and sequencing library preparation methods. This classifier is complementary to the 
public/private TCR clone classifier “PUBLIC”, which accurately predicts shared TCR clones between two 
people or an arbitrarily large number of individuals54. Specifically, based on T-cell immune receptor 
generation probabilities, and extrinsic factors such as cohort size, sequencing depth, and a definition of 
what constitutes as a public receptor, the Walczak group suggests that the degree of publicity of a given 
TCR clone is largely dependent on the probability of its generation through V(D)J recombination.  
 
While over the last few years there has been considerable interest in the classification of antigen or epitope-
specific sequences, there has been relatively less conceptual progress on the classification problem of the 
immune status based on entire repertoires (per individual samples). Briefly, there is a conceptual difference 
in machine learning between sequence-based (prediction of antigen specificity) and repertoire-based 
classification (prediction of immune status). While in the sequence-based case class labels are assigned in 
a binary or multi-class fashion to a single-sequence (for example: sequence 1→ class 1 – binding to HIV, 
sequence 2 →  class 2– binding to Tetanus), labels in the repertoire classification case are given to a set of 
sequences. The assumption is that within a repertoire there exist sequences or subsequences (single or sets 
of sequence motifs) that are overrepresented in one class compared to all other classes. The particular 
challenge in this case is that the signal-to-noise ratio in immune repertoires is unknown but likely very low 
(although, for example, in the case of CMV, nearly 10% of T-cells are CMV-specific93). Specifically, the 
disease signal in the form of sequence (motifs) likely represents a high-dimensional mixture of different 
motifs. Machine learning approaches to disentangle and recover these high-dimensional signals are as of 
yet missing94. Nevertheless, progress has been made in terms of repertoire-based diagnostics in mouse and 
humans with both model antigens and virus infections leveraging both sequence motifs and entire 
sequences25,82,95–98. Machine learning approaches for repertoire-based diagnostics range from Bayesian 
classifiers, support vector machine and very recently multiple instance and deep learning. While all of these 
approaches show considerable prediction accuracy, the identification of disease-status driving sequence or 
sequence motifs remains difficult. Emerson and colleagues solved this problem by exclusively working on 
public clones and consequently identifying clones that were associated with CMV status using Fisher’s 
exact test25. However, there might also be considerable disease-associated information in the private portion 
of each repertoire. It remains a general and important problem how immune-relevant information, that is 
seemingly variable within classes and thus private, may be leveraged for disease-state classification99. In 
addition to disease or antigen-specific information spread among public and private parts of the repertoire, 
several studies have shown an HLA-effect on repertoire structure with public clones or germline genes 
being specifically linked to certain HLA-types25,58,100. It remains unclear to what extent HLA-induced 
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repertoire structures would bias disease-specific repertoire classification and to what extent repertoires 
ensembles are characteristic of a certain HLA type101,102.  
 
More generally, given that pathogen diversity drives human MHC evolution103 and the personalized nature 
of epitope repertoires104, certain pathogen groups influence MHC evolution more than others depending on 
the environment. Thus, as adaptive immune repertoire analysis moves towards more clinically focused 
questions and larger cohorts, evolutionary and epidemiological approaches will be needed to appropriately 
take covariates such as environment, age105–108 and genetic confounders58 into consideration when 
performing privacy-preserving and ethics-conform disease-specific immune receptor-based 
classification109. Ostermeyer and colleagues found that their classifier generalized well across individuals 
with presumably different HLA backgrounds82. The authors hypothesized this because of two reasons: (1) 
TCR-MHC interaction occurs primarily via CDR1 and CDR2 whereas peptide contacts are primarily via 
CDR3 and (2) their study design included HLA-matched controls82. 
 
Of note, while HLA-restriction of T-cell repertoires has garnered increased attention, investigations as to a 
potential HLA-restriction of antigen-specific B-cell repertoires has not been explored to our knowledge. B-
cell activation and germinal center reaction are, in part, T-cell dependent, which may have an impact on 
which B cells receive appropriate signals to participate in the humoral immune response.  
 
Mathematical modeling of immune receptor recognition  
Manipulation of adaptive immunity by either in vitro immunoengineering of immune receptor 
repertoires110–112 or in vivo (no reports yet to our knowledge) depends on the underlying recognition 
dynamics of immune cells. One of the earliest theoretical studies on immune receptor recognition was 
performed by Perelson and collaborators summarized comprehensively by Perelson and Weisbuch113. 
Perelson and Weisbuch worked on the mathematical modeling of the immune system from the viewpoint 
of how such a complex system can achieve recognition and memory of a nearly limitless number of antigens 
by at the same time being restricted by (i) immune cell number, (ii) B and T-cell clone size and (iii) 
immunogenetics (germline gene repertoire). So far, the maximum number of antigens to which the human 
immune system can build a memory response remains unclear114. Specifically, one of the main questions 
of Perelson and Weisbuch is the problem of repertoire completeness – where completeness describes the 
extent to which immune repertoires have the potential to recognize any given antigen. Repertoire 
completeness is an old problem that has received relatively little attention as of late, despite its importance 
for immunoengineering. Indeed, prior to modifying the binding landscape of immune repertoires via in 
vitro or in vivo engineering, detailed knowledge of the a priori immune receptor binding landscape is 
needed.  
 
To mathematically simulate binding of antibodies to antigen, bit strings (string models) are often employed 
to represent antibodies as well as antigens113,115–117. Antibody and antigen sequences are only composed of 
two “amino acids”, 0 and 1 (binary models). The patterns of the bits represent the shapes of molecules and 
determine their ability to bind with other molecules115. In the bit string methodology conceived by Farmer 
and colleagues, molecular binding takes place when the bit strings of antibody and antigen “match” each 
other. A match occurs when the antigen and antibody have complementary binary patterns116. Interestingly, 
in their work, Farmer and colleagues attributed the ability of the immune system to learn, retain memory, 
and recognize patterns (antigens) to its capacity to employ genetic operators such as gene rearrangement 
and mutations without a priori programming. They developed a (dynamical) model that simulates the 
behavior of an immune system in silico. The model shares many commonalities with a general purpose 
machine learning/artificial intelligence algorithm that was being introduced in the same year by J.H. 
Holland called the classifier system118. The similarities not only include the absence of a priori programing 
to achieve the corresponding final goals (immune system: antigen recognition; general learning: class 
discrimination) but also extend component-wise. For example, in the classifier system the classifier, 
condition, and action components are likened to antibody type, epitope, and paratope components of the 
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immune system (for detailed component-wise comparison, see Table 1 in Farmer et al.115). In a recent 
article, Efroni and Cohen further expand on the idea of the immune system “classifying” and “computing” 
the state of the body in a fashion similar to machine learning119. 
 
Bit string approaches were also explored in vitro: for example, Fellouse and colleagues120 obtained 
functional antibodies from a library of antigen-binding sites generated by a binary code restricted to tyrosine 
and serine. An antibody raised against human vascular endothelial growth factor recognized the antigen 
with high affinity and specificity in cell-based assays. 
 
A challenge for shape space (see Focus Box 2) and binary models is their discretization of the affinity 
space121. An overview of alternative models was recently summarized by Robert and colleagues121. For 
example, string model approaches aim to simulate antibody antigen recognition in 3D-space121 now enable 
the modeling of cross-reactivity. Specifically, structural representations of amino acid sequences on a 3D 
grid have been proposed using an experimental interaction matrix between each pair of amino acids122. The 
respective best-folding structure of antibody and antigen is computed for both proteins, possible binding 
interfaces are computed, and the best affinity is recorded.  
 
Recently string models have been applied to research questions ranging from B-cell epitope prediction to 
understanding multi-epitope recognition. For example, Greiff and colleagues used string models to simulate 
the binding of arbitrarily large antibody mixtures to peptide libraries and showed that both antibody 
repertoire diversity and antibody concentration within a repertoire may be crucial to humoral immune 
recognition123. Furthermore, Wang and colleagues recently used string models to model selection forces 
during germinal center affinity maturation. Specifically, they used such in silico models to gain mechanistic 
insights into the processes of affinity maturation that are induced by multiple antigen variants, and to 
compare the predicted relative efficacy of different immunization schemes in inducing cross-reactive 
broadly neutralizing antibodies. They found that induction of cross-reactive antibodies often occurs with 
low probability because conflicting selection forces, imposed by different antigen variants, can “frustrate” 
affinity maturation. There exist competing theories about frustration which are rigorously summarized by 
Robert and colleagues121. In another example of string modeling, Luo and colleagues generated new 
hypotheses regarding the difficulty of predicting the emergence of broadly neutralizing antibodies. By 
modeling antibodies as single strings and viruses as double strings (simulating one variable and one 
conserved epitope on the HIV envelope protein), they found that broadly neutralizing antibodies could in 
fact emerge earlier and be less mutated, but that they may be prevented from doing so as a result of 
competitive exclusion by the autologous antibody response. If less mutated broadly neutralizing antibodies 
exist, they posit, it may be possible to elicit them with a vaccine containing a mixture of diverse virus 
strains124. In summary, even seemingly simple string model scan provide insight into engineering optimal 
therapeutic antibodies and vaccines by modeling the paratope-epitope interface.  
 
Computational modeling of immune receptor 3D structure  
The majority of immune receptor sequence studies are performed on the linear (2D) V(D)J sequence, or a 
sub region thereof (mostly CDR3). However, immune receptor antigen interaction is inherently 3-
dimensional. Consequently, residues that are distant in the linear sequence space may be very close to one 
another in the 3D space due to folding. Computational prediction of immune receptor structure is important 
in view of the unresolved technical and resource-imposed challenges related to experimental immune 
receptor structure determination. Rational therapeutics and vaccine design depend on 3D-modeling of 
immune receptor antigen binding pairs. In this review, we focus on (3D) antibody structure and antibody-
antigen interaction. For TCR-based 3D modeling and engineering, we point the reader to recent works on 
the subject125–131.  
 
In the 3D-space, the CDRs form loops. These loops can be categorized into canonical conformations 
depending on the 3D-length. However, the longer the CDR the harder it becomes to predict spatial 
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conformation – especially that of the CDR3132.  Typically, the CDR-H3 loop does not adopt canonical 
conformations and must be modeled de novo for maximum accuracy. In addition, the H3 loop lies at the 
interface of the two variable domains of the heavy (VH) and light chains (VL) and can interact with residues 
on either chain. To account for these interactions, as well as the overall geometry of the paratope, the VL-
VH orientation is usually optimized during H3 modeling. Accurately modeling CDR H3 and the VL-VH 
orientation are typically the most challenging and critical aspects of antibody structure prediction133,134. 
 
The Gray lab has substantially contributed to computational 3D antibody structure calculations by co-
developing antibody structure determination within the Rosetta software framework134,135. Briefly, Rosetta 
antibody structure modeling involves identification of the most homologous template structures for heavy 
and light framework regions and each CDR loop. Subsequently, the most homologous templates are 
assembled into a side-chain optimized model. For a high-resolution model, additional modeling of the 
hypervariable CDR-H3 loop is performed by also relieving steric constraints optimizing the CDR backbone 
torsion angles and perturbing the relative orientation of the heavy and light chains. Based on the Rosetta 
Framework, the Gray lab has also developed an antibody-antigen docking software (SnugDock134,136). It 
takes as input antibody-antigen structures. Specifically, SnugDock simulates the induced-fit mechanism 
through simultaneous optimization of several degrees of freedom. It performs rigid-body docking of the 
multibody (VH-VL)-Ag complex, as well as remodeling of the CDR-H2 and -H3 loops. 
 
While the RosettaAntibody software may use up substantial computing hours to perform antibody structural 
modeling (≈1000 CPUh/antibody) due to ab initio modeling, the Charlotte Dean lab has developed an 
alternative antibody structural modeling approach based on database-search driven homology modeling, 
which enables CPUh-saving modeling of large numbers of antibody sequences137 relying on the structural 
conservation of antibody shapes. Specifically, Kawczyk and colleagues structurally mapped 35 million 
antibody sequences from 600 individuals. They have developed a structural annotation of antibodies 
(SAAB) algorithm to bridge the sequence-structure gap in antibody repertoire analysis.  Given a fasta file 
of antibody sequences (may be unpaired), SAAB maps the full sequences, frameworks, and CDRs to the 
high-quality antibody structures currently available in the Protein Data Bank (PDB). The Dean lab 
associated a majority of frameworks and CDR sequences to an existing antibody structure, thereby 
recapitulating on a large scale that the observed antibody sequence space appears to employ only a 
conservative set of structural shapes. The SAAB algorithm is based on the methods ABodyBuilder 
(antibody modeling pipeline based in part on FREAD]138 and FREAD protocols –loop structure prediction 
using a database search algorithm)139 that produce models of the variable regions and protein loops. 
 
In summary, in silico prediction of antibody structure is possible with reasonable accuracy and speed, at 
least for antibodies with moderate CDR3 length.  
 
Computational modeling of antibody-epitope interaction 
It is generally thought that the CDR3 is the most important region for antigen binding140,141. However, at 
least for antibodies, it has been found that the framework regions can contribute up to 20% to antigen 
binding thereby expanding our view of what constitutes the antibody antigen binding site142. Furthermore, 
not all the residues within the CDRs bind the antigen. Only up to 5 of these amino acids dominate in terms 
of binding energy. In both epitope and paratope, substitutions both in and away from the binding site can 
change the spatial conformation of the binding region and affect the binding reaction143–146.      
 
In general, antibody CDRs have a much greater frequency of tyrosine and tryptophan residues than usually 
found on the surface of protein molecules143,147. These aromatic side chains can make large rotations with 
little entropic cost, and they contribute significantly to the binding energy148. Furthermore, crystallographic 
studies showed that binding involved a certain amount of induced fit149. Upon binding, residues are 
displaced by several angstrom150. In fact, two molecules that have nearly identical structures on the basis 
of crystallography may not interact comparably with a given receptor because of differences in molecular 
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dynamics151: the crystallographic structure of an antibody-antigen complex captures merely one point in 
time. The contributions of the time dimension should therefore, ideally, be taken into account for a 
characterization of bimolecular interactions152,153. Hence, Greenspan proposed a richer epitope description 
by taking into account (i) the spatial coordinates of the contact atoms, (ii) the dynamics in time of the atoms 
involved in contact with the paratope, (iii) the relative energetic contributions of atoms or amino acids to 
the interaction or to the discrimination between cognate epitopes and other epitopes, and (iv) the context in 
which the binding takes place152,154. 
 
While specificity has been primarily discussed in the literature in the context of monoclonal antibodies, 
monoclonal specificity does not per se explain humoral specificity. Indeed, despite antibody polyspecificity 
(cross-reactivity), the population of serum antibodies as a whole shows a high degree of specificity towards 
the eliciting antigen155. Serum specificity provides the very basis for the clearing of pathogenic agents from 
the body. Talmage suggested that “in a mixture of a large number of different globulin molecules, the 
dominant reactivity will be that common to the largest number of molecules present”156. Serum specificity 
may therefore be regarded as an ensemble phenomenon of serum antibodies 123,155,157,158.  
 
The ability to predict B-cell epitopes for a given protein precedes digitized vaccine design159 and 
diagnostics. Epitope prediction is often done by immunizing the host with the antigen followed by profiling 
the resulting serum-antibody response with a wide array of methods. Some of these are shortly outlined in 
this section. Although it is believed that the majority (>90%) of B-cell epitopes are discontinuous 
epitopes144, the experimental determination of epitopes has focused primarily on the identification of 
continuous B-cell epitopes160. Apart from X-ray crystallography, which represents a structural approach to 
epitope mapping90,161,162, important experimental techniques to map epitopes  (and receptor cross-reactivity) 
are phage-display libraries163, peptide arrays164–167 and site-directed mutagenesis168.  
 
Several computational methods for prediction of continuous B-cell epitopes have been published in recent 
years. Propensity scale methods assign a propensity score to each amino acid that measures the tendency 
of an amino acid to be part of a B-cell epitope (as compared to the background)169–174. However, Blythe and 
Flower have assessed 484 amino acid propensity scales to examine the correlation between propensity 
scale-based profiles and the location of linear B-cell epitopes in a dataset of 50 proteins. Their study showed 
that even the best combinations of amino acid propensities yielded B-cell epitope predictions that were only 
marginally better than random175,176. Due to the poor results yielded by propensity scales alone, several 
authors have explored methods for improving the predictive performance of propensity scale methods by 
combining them with Hidden Markov models or support vector machines177,178. However, the combination 
of scales with several machine learning algorithms showed little improvement over single scale-based 
methods179,180. 
 
Given that  immunogenicity of proteins is poorly understood, it remains an open question whether B-cell 
epitopes could be deciphered as intrinsic features of proteins after all176,181. One possible explanation for 
the failure of B-cell epitope prediction methods based on amino acid characteristics is that the amino acid 
differences between epitopes and other residues are not substantial. In line with this argument, several 
analyses145,182–185 have shown that the amino-acid composition of epitopes is essentially indistinguishable 
from other surface-exposed non-epitopic residues. This lack of intrinsic properties to clearly differentiate 
between epitopic and non-epitopic residues and the fact that most of the antigen surface may become a part 
of an epitope under some circumstances179,186 suggest that epitopes depend, on the antibody that recognizes 
them, as suggested above . Indeed, T-cell epitope prediction methods are MHC- and thus context-
dependent187. 
 
Recently, B-cell epitope prediction methods have been proposed that take into account also the antibody 
sequence. These methods are motivated in part by: (i) the success of partner-specific protein-protein 
interface predictors188,189 as well as  allele-specific MHC binding site predictors190,191; and (ii) the 
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observation that virtually any surface accessible region of an antigen can become the target of some 
antibody and elicit an immune response192,193 hence requiring focus of epitope predicting for a given specific 
antibody.  Antibody-specific B-cell epitope prediction methods take into account the binding antibody 
sequence or structure in order to predict conformational B-cell epitopes in a query antigen sequence of 
known structure194–198. Very recently, Jespersen and colleagues identified several geometric and 
physicochemical features that are correlated in interacting paratopes and epitopes, used them to develop a 
Monte Carlo algorithm in order to generate putative epitopes-paratope pairs, and train a machine-learning 
model to score them. The authors showed that, by including the structural and physicochemical properties 
of the paratope (e.g.,: hydrophobicity, size, Zernicke moments199), they could improve the prediction of the 
target for a given BCR.  
 
Very recently, the Wardemann and Julien labs have uncovered that affinity maturation does not only 
increase diversity and affinity200 but also homotypic interaction between repeat-bound monoclonal 
antibodies201. Somewhat relatedly, the Högberg lab has investigated isotype-specific differences in binding 
to nanopatterned antigen showing that antibody affinity changes with antigen-to-antigen-distance202. Thus, 
the complexity of antibody-antigen interaction is even higher than previously thought.   
 
Taken together, modeling of immune receptor-antigen interaction still requires extensive investigation, 
most importantly in the areas of large-scale experimental generation of receptor-antigen pairs as well as 
machine learning methods that enable to define the rules of receptor-antigen interaction.  
 
 
Genomic sequencing of immune repertoires  
High-throughput immune receptor repertoire sequencing has so far mainly revolved around single-chain 
characterization (either α or β for T cells and predominantly VH for B cells) due to the fact that standard 
«bulk» sequencing approaches fail to capture natural pairing of α/β and heavy/light chains because they are 
encoded by separate mRNA transcripts. Chromosomal separation of B-and T-cell chain loci has made 
single-cell immune receptor sequencing an extremely challenging and laborious task. Nevertheless, the 
information on cognate pairing is essential for the structural modeling and further immune receptor 
engineering as the entire receptor complex determines stability, conformation, half-life, and specificity203–
205. 
 
Until recently, the wide use of single-cell sequencing techniques has been impeded by several factors, such 
as low yield, low throughput and high costs. Introduction of microfluidic devices allowing to separately 
analyze hundreds of thousands of cells significantly improved analytical capabilities206. There is still a 
major difference in throughput between microfluidic platforms varying from 2–3 to millions of isolated 
single cells per run (Table 1). However, rapid evolution of the technology, along with decreasing costs, 
may soon provide the possibility for routine single-cell sequencing with a magnitude comparable to 
conventional bulk sequencing (millions of input cells). 
 
After single-cell capture and subsequent cell lysis, mainly two strategies are currently used to retrieve full-
length paired receptors. (i) Receptor chains may be paired by means of overlap-extension PCR within 
droplets as it was demonstrated by DeKosky and colleagues for BCRs and by Turchaninova and colleagues 
for TCRs207,208. The main disadvantage of such approaches is Illumina read-length limit (2x300 bp) that has 
prevented so far, the characterization of full-length paired sequences. (ii) An approach that might overcome 
this issue relies on the separate labeling of mRNA transcripts by a set of unique molecular identifiers 
(UMIs). These UMIs might be directly co-encapsulated along with cells209, delivered into droplets being 
attached to a bead surface as it is performed in protocols by 10xGenomics, or appended to transcripts 
through a sequence of labeling steps210. Although UMI usage is associated with a number of technical 
challenges (including the necessity of precise single-molecule dilution and complex design of several 
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sequential in-droplet PCRs) and relatively high costs4, this technique has dramatically improved error 
correction of single-cell sequencing, thereby improving data reliability and confidence211–213. 
 
The understanding of antigen-specific immune repertoires remains limited due to the current technological 
challenges to link immune receptor and cognate antigen at high-throughput. While single-cell analysis has 
gained momentum in the last few years and many sequencing technologies that have been developed to 
advance our understanding of antigen-specific immune repertoires, not one method has emerged as a 
breakthrough technology with wide adoption. There is considerable variability in the cost, ease of 
implementation, throughput, and depth of information that can be generated from these single-cell immune 
repertoire sequencing and selection methods. To illustrate this point, in Table 1 we summarize the majority 
of the most recently published single-cell sequencing protocols currently in use, and their key differences. 
 
Identifying candidate TCRs or antibodies via high-throughput library screens 
In the domain of antibodies, major advances have come out of in vitro techniques to express and select 
epitopes by phage and yeast display. Notably, Andrew Bradbury’s work on developing a recombination 
system in singly infected bacteria expressing Cre recombinase provided a simplified means of generating 
functionally rearranged VH/VL libraries with diversities of >1011 214. Generation and screening of these 
combinatorial display libraries has rapidly accelerated the process of antibody development. As a result, 
recombinant antibody-based products have entered the biopharmaceutical market28,215,216. Through the 
integration of paired antibody sequencing and yeast display libraries, new high throughput pipelines can 
now be used to interrogate millions of natively paired antibodies in humans217.  Germline targeting of 
condition-specific antibodies, paired with high-throughput library screens, has also shown promise in 
detecting broadly neutralizing antibodies in HIV and is further described in Section Setting targets on public 
and private immune receptors of this review. 
 
In the context of TCRs, efforts to identify and interrogate TCR targets and cross recognition have been 
primarily accomplished through barcoded peptide-major histocompatibility complex (pMHC) 
multimers218–221 and yeast display libraries125,222,223. Recently Gee et al. crucially demonstrated that pHLA-
A∗02:01 yeast display libraries (in the order of ~108 unique peptides) could be used to in a non-biased 
manner screens for high-affinity orphan TCRs derived from tumor infiltrating lymphocytes expressed on 
human colorectal adenocarcinoma223. Zhang and colleagues have also developed TetTCR-seq to link TCR 
sequences to their cognate antigens in single cells at high throughput by exploiting  DNA-barcoded pMHC 
tetramers224. With this technology, the authors were able to readily investigate cross-reactivity with neo-
antigens and to rapidly isolate neoantigen-specific TCRs with no cross-reactivity to the wild- type antigen. 
TetTCR-seq would also integrate with single-cell transcriptomics and proteomics to investigate links 
between single T-cell phenotype, TCR sequence and pMHC-binding. Relatedly, Bentzen and colleagues 
developed two approaches that enables in-depth characterization of TCR recognition patterns that govern 
pMHC interaction218,219. Specifically, they used DNA barcode-labeled MHC multimers, which allows the 
simultaneous study of the interaction of one clonal TCR with multiple related pMHC epitopes. By 
measuring TCR affinity to bound pMHC, this workflow also shows promise in predicting and validating 
cross-reactivity of TCRs219. Assessing cross-reactivity is an essential step in validating any candidate TCR 
in clinical development. However, directly identifying cross-reactivity to the human proteome, at the time 
of candidate TCR identification, is an important technology advance. Wide implementation of this practice 
could decrease the time needed to validate new TCRs being considered for use clinically. A major limitation 
to the yeast display libraries and barcoded pMHC approaches, however, is the requirement of either soluble 
TCR or soluble pMHC, which does not directly mimic TCR-pMHC in a physiological setting. 
 
Two approaches capable of deciphering TCR specificity using cell-cell binding interaction,  have recently 
been developed by the Kopf and Baltimore groups225,226. Both approaches attempt to identify TCR 
specificity utilizing a chimeric HLA extracellular domain fused to TCR downstream signaling elements 
and signaling via CD3ζ and an NFAT reporter. Key differences between these two approaches is that Kopf’s 
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MHC–TCR chimeric receptors identify orphan CD4+ T cell epitopes via extracellular domains of MHC-
II225, and Baltimore’s platform targets CD8+ T cells epitopes through MHC Class I extracellular domains226. 
While the latter has the disadvantage of decreased sensitivity (detection sensitivity of 1:104 vs. 1:106), the 
approach can be uniquely performed in a single round of selection.  
 
Collectively these approaches highlight the challenge of identifying candidate TCRs or antibodies, and the 
tradeoffs in terms of detection sensitivity, library, diversity and ability to accurately replicate physiological 
binding interactions. 
 
Proteomic sequencing and serological profiling of antibody repertoires  
Remarkably, despite major advances in immunology research and sequencing strategies, comprehensive 
knowledge of the circulating antibody repertoire including specificity, function, and clonality remains 
scarce. Indeed there is no consensus on the quantity of distinct antibody types in the blood with numbers 
estimated from 103 to 106 227,228. This knowledge gap significantly hinders extensive understanding of 
serological humoral immunity, such as for example vaccine-induced antibody dynamics. 
The immense antibody diversity, the little overlap across individuals, combined with high structural 
immunoglobulin similarity, renders the characterization of the serum antibody repertoire challenging. As 
outlined by Wine and colleagues, methods to study the circulating antibody repertoire may be divided into 
two major groups: phenotyping (e.g. ELISA, serum electrophoresis, etc.) and deciphering (LC-MS/MS )228. 
While the techniques from the former set of methods dominated immunology for decades, they are unable 
to grasp the sequence diversity of serum antibody repertoires. Availability of LC-MS/MS (mass 
spectrometry) technology with its high throughput (and previously unachievable specificity and sensitivity) 
enabled characterization of circulating immunoglobulins with resolution superior to any other analytical 
methods. Specifically, in 2012, Cheung and colleagues published the first paper describing direct 
identification of antibodies (CDR-H3 peptides) from serum using high-throughput B-cell receptor 
sequencing data as a reference229. Recently, Lee and co-authors described a novel class of non-neutralizing 
antibodies abundantly presented in the circulation of individuals immunized with influenza vaccine230. They 
also found in a human donor, of which the influenza serum antibody response was followed for several 
years, that 24 persistent antibody clonotypes accounted for ≈70% of the anti-H1N1 A/California/7/2009 
repertoire indicating the astounding stability of the serum antibody repertoire231. 
 
It is worth mentioning that in order to exploit its full analytic potential, LC-MS/MS technology requires 
robust reference datasets generated by high-throughput sequencing, although the number of tools for de 
novo sequences identification is increasing232. Moreover, overall high costs and technical complexity along 
with additional infrastructure requirements currently prevent broad application of antibody serum LC-
MS/MS. 
 
While mass-spectrometry-driven antibody proteomics has the power to analyze serum antibody diversity, 
the breadth of antibody binding is most effectively analyzed using serological profiling by peptide and 
protein microarrays, which are devices with up to millions of peptides233,234  or proteins235,236 from either 
self-peptides, disease agents or random-sequence peptides.. Antibody binding to peptides is measured via 
fluorescently labelled secondary antibodies leading to signal intensities which are high for peptides which 
are bound by large numbers of antibodies and low when few antibodies bind. Antibody profiling studies 
may be roughly divided in two types150. (Type I) Epitope mapping studies: here, peptide signal intensities 
are interpreted as a reflection of the peptides’ function (eliciting antigen and/or epitopes) in the studied 
disease. These approaches, therefore, mostly use autoantigen or disease-dedicated peptide libraries to detect 
and identify potential disease-antigens237,238. Type II peptide microarray approaches interpret measured 
signal intensities in relative terms and antibody polyspecificity239. The relative differences in binding 
patterns between the healthy and the diseased case represent the main finding. The fact that polyspecificity 
of antibodies renders the nature of the eliciting antigen(s) unimportant makes random-sequence peptide 
arrays, which are primarily used in this type of approach, a relatively cheap, unbiased, non-pathogen-
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restricted, and user-friendly tool for serological diagnostics240,241. Indeed, it was even hypothesized by 
Navalkar and colleagues that random-sequence peptides are more useful than tiling proteome sequences242 
for immunodiagnostic purposes. The reason for this may be that common motifs and protein structures are 
shared among many distantly related organisms. It may even be that in some cases, random sequence 
peptides have a higher number of 5-mer sequence overlap with the target proteome than peptide epitopes 
thought to be related to the target epitome184,242.  
 
Recently, a potential alternative to peptide arrays has been developed: PhIP-Seq (phage 
immunoprecipitation sequencing’) combines oligonucleotide library synthesis with high-throughput DNA 
sequencing analysis of phage-displayed libraries. Compared with peptide microarrays, PhIP-Seq features 
longer and higher-quality peptides243. The synthetic oligonucleotide libraries are designed to encode peptide 
tiles that together span a library of protein sequences (entire proteomes, for example). The result is a 
representation of the encoded peptides. Deep DNA sequencing of phage-displayed peptidomes permits the 
quantification of each peptide’s antibody-dependent enrichment thereby allowing the measurement of 
antibody specificity. PhIP-Seq has been applied to measuring the serum antibody against large viral peptide 
libraries244 or to measure the repertoire of maternal anti-viral antibodies in human newborns245. 
 
One of the major remaining challenges of peptide arrays studies (or other serological profiling platforms) 
is the deconvolution of the binding signal exerted by each of the serum composing antibodies. Georgiev 
and colleagues showed that, at least in the context of HIV epitopes, the antibody binding signal of the serum 
circulating antibodies can be mathematically deconvolved to a certain extent if binding data exist of those 
monoclonal antibodies that are putatively in the serum. Current scalability issues of antibody expression 
(Fig. 1), however, render these experiments challenging on a larger scale.  
 
While serological profiling represents a useful tool for mapping and uncovering antibody epitopes, mass 
spectrometry remains the only technology for comprehensively mining in vivo peptides presented to T cells 
via MHC. There has been considerable focus on leveraging mass spectrometry based imminopeptidomics 
to interrogate of HLA-peptide diversity and APCs for naturally processed peptides derived from tumor 
associated antigens246. Currently, there is an ongoing debate as to whether it is more effective to target 
hotspot drivers of cancer mutation or track private neo-antigen moving targets247–249. Identifying private 
neo-antigens has proven challenging, as identification requires the screening of enormous synthetic peptide, 
or fusion gene-libraries, and often involves procurement of rare and/or invasive patient samples.  In spite 
of this challenge, several studies have developed personalized neoantigen vaccines which selectively 
expand antigen specific T cells and result in selected patient remission250–253. Of note, one of these studies 
was implemented in a phase I/Ib clinical trial for glioblastoma, a particularly low mutational burden 
tumor253. Together, these clinical success stories highlight the utility and impact of these 
immunopeptidomic approaches, and the potential to integrate deep learning to assist in the identification of 
(neo)antigens254,255 and neoantigen-reactive T cells256. 
Future directions for quantitative immunoengineering and immune receptor 
analysis 
 
Setting targets on public and private immune receptors 
Within the immune receptor landscape, instances occur where a given immune receptor is found in multiple 
people. These receptors are commonly called “public receptors” and they have been identified in health but 
also in numerous malignancies, infectious diseases, and autoimmune diseases20,257–263. Their detection 
requires brute force high-throughput paired-sequencing across large cohorts8,9,56 or recently developed 
classifiers based on generation probabilities54 and sequence motifs91. 
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As of yet, the biological purpose of public clones remains unclear. It has been hypothesized that their 
function is to recognize and neutralize common pathogens63,91. However, definitive proof is still missing. 
We have previously published anecdotal evidence that murine B2-public clones show a higher overlap than 
B2-private clones with murine B1-B cells91. B1-B-cells are thought to bind common pathogens264. 
Relatedly, the Rajewski lab has showed that B1- and B2-B-cell lineage decisions depend on self-reactive 
signaling of the BCR. The inherent BCR-driven link between B1 and B2 suggests that the dynamics of the 
(public) repertoire potentially responsible for common pathogens is highly flexible and may not be entirely 
evolutionary encoded but rather environment-driven. In that regard, public clones may provide a pathway 
to identifying the functional limits of the adaptive immune system’s target binding capacity as well as an 
indirect way of quantifying the frequency of antigen encounter throughout evolutionary time. 
 
Apart from the fundamental immunological understanding of immune receptor publicity, its prediction may 
be important for population-wide targeting of immunotherapeutics56. Indeed, given the inherent complexity 
and overwhelming individuality of immune repertoires, public clones may represent predictable therapeutic 
“safe harbors” for antigen-specific targeting.  Specifically, in recent years, vaccine design has begun to 
crack open the vision of targeting public clones for therapy by leveraging high throughput sequencing and 
structure guided design. In the case of HIV, high-throughput sequencing in a large-scale longitudinal study 
has identified BnAbs to HIV, which appear as public clonotypes, suggesting these public targets may be 
clinically valuable as they provide an opportunity to elicit by vaccination a few very potent therapeutic 
antibodies to treat many HIV infected individuals258. The capacity of public targets to independently arrive 
at the same clonotype against a given antigen, is an important demonstration of convergent evolution in 
immunology and suggests that public clones may act as crucial nodes in repertoire networks77. Germline 
targeting of condition-specific antibodies has also emerged as a promising competing approach to 
identifying antibody precursors with broadly neutralizing properties to modified immunogens265,266. Jardine 
and colleagues demonstrated using germline targeting through a highly interdisciplinary approach 
combining structure-guided protein interface design, yeast display libraries, and next-generation 
sequencing. Using this approach, they were ultimately able to develop a modified HIV immunogen with 
affinity for the germline-precursors of VRC01-class broadly neutralizing antibodies. While this germline 
targeting approach has been done in the context of antibodies, the work highlights an approach which could 
be co-opted to logically generate antigen specific T cells educated from on known private sequences and 
tailored immunogens. Germline targeting presents an opportunity to identify and expand condition specific 
TCRs and BnAbs where traditional methods fail to elicit these responses. In Focus Box 2, we discuss the 
possible implications the presence and absence of public BnAbs to HIV has on repertoire recognition holes. 
 
Finally, in the context of T-cells specifically, public clones present themselves as an attractive target for 
engineered T-cell receptors and CAR-T therapy. Recent studies identifying public TCR recognition of the 
GAG peptide (protein encoded by retroviral genomes like HIV) revealed that these clones also display a 
high degree of promiscuity in their ability to bind many diverse HLA-DR allomorphs257. The ability of 
public TCRs to recognize an array of HLA, highlights the utility of public TCRs as this could allow some 
clones to be utilized across an array of patient HLA haplotypes. Related to that, the Friedman lab has 
identified, among peripheral T cells, MHC-independent public TCRβ CDR3 sequences that are abundant 
with fewer N insertions than average267. And very recently, the Brusko lab provided evidence that thymic 
selection is involved in the formation of public TCR clones21. 
 
 
Efficient modification of immune receptor activity in vitro and in vivo 
The humoral immune response elicited by vaccines efficiently triggers B-cell activation, somatic 
hypermutation, class switching, and the development of long-lived plasma and memory B cells which 
deliver enhanced protective and neutralizing responses268. It is also known that protective humoral immune 
responses are not always triggered by affinity maturation of the immunoglobulin repertoire, and that 
vaccines for common pathogens could not be developed. Even with identified sequences for protective 
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monoclonal antibodies from many of these pathogenic targets, developmental vaccines often struggle to 
recapitulate the broadly neutralizing antibody responses present in elite controllers269. Using CRISPR/Cas9 
mediated homology directed repair (HDR), it is now possible to introduce by targeted integration B-cell 
transgenes into hybridomas or primary human B-cell lines and exchange antibody specificity. Proof of 
principle of reprogramming the antigen specificity of B cells using modern genome-editing technologies 
was first demonstrated by the Reddy lab using the plug-and-(dis)play platform270.  Here hybridomas were 
designed to remove endogenous copies of heavy and light chains, and full-length light and heavy chains, 
under the native IgH promoter, were expressed as a single transcript. Similar hybridoma CRISPR/HDR 
reprogramming has expanded upon this idea to generate on-demand class switching of recombinant 
monoclonal antibodies271. 
 
Recently, this concept has been applied to directly introduce well characterized protective paratopes of 
broadly neutralizing HIV antibodies via CRISPR/Cas9 mediated HDR into mature B cells. The goal of 
CRISPR-based lymphocyte engineering is to circumvent current challenges of generating HIV neutralizing 
responses via vaccination269 or directed germline expansion265,266. The study is the first to describe a 
successful genome editing approach for introducing novel antibody paratopes into the human repertoire 
through BCR modification in polyclonal human B cells272. This approach replaces existing rearranged 
heavy chains with protective heavy chain paratopes derived from HIV broadly neutralizing antibodies. 
Recently two additional groups have independently developed alternative approaches utilizing 
CRISPR/Cas9 to reprogram murine and human B cells to also generate bnAbs to HIV110,112. While both 
groups demonstrated the utility of their approach using both naive primary human and mouse B cells, Taylor 
and colleagues demonstrate their system can reprogram B cells to generate bnAbs for not only HIV but also 
respiratory syncytial virus (RSV), influenza, and EBV. The B cell VDJ locus is also uniquely designed to 
retain physiological expression of the inserted monoclonal antibody and natural isotype class switching112. 
These preliminary results also suggest that after intranasal challenge with RSV, naïve B cells with 
genetically engineered receptors may be capable of establishing long-lived in vivo protection through 
generation of plasma-like and memory-like B cell populations. While initial results from these studies are 
promising, robust surface marker and transcriptional characterization of these cells is needed to verify that 
these cells are indeed long-lived, quiescent, and terminally differentiated B-cell populations273. 
 
Engineered TCRs have emerged as a promising immunotherapeutic strategy. Unlike antibodies, T cells lack 
the ability to undergo somatic hypermutation (with sharks being one of the few exceptions274), which 
contributes to a higher target specificity on the part of antibodies128. To better emulate the affinity 
maturation process, present in antibodies, many groups have attempted to develop ways which mimic this 
process for T cells. In recent years, there have been numerous studies to increase the affinity of a T cell to 
target antigen275,276. Unfortunately, clinical utilization of some engineered T cells has inadvertently shown 
that enhancing target affinity magnifies a latent capacity for TCR cross reactivity to non-target epitopes. 
For example, in one instance an affinity enhanced TCR was cross reactive to a peptide derived from the 
muscle protein Titin, causing lethal cardiovascular toxicity277. To combat this issue, it has recently been 
suggested that TCRs may be made to be more specific to a target antigen via the incorporation of both 
positive and negative design278. A recent review has expanded upon this idea to suggest that structural and 
predictive modeling will be essential in guiding design to identify these key mutations to maximize binding 
and specificity of TCRs131. Utilizing this approach would require positive design mutations with 
strengthening interactions between TCR and its cognate antigen/MHC, while introducing additional 
negative mutations which weaken evolutionarily conserved amino acids that control TCR-MHC 
interaction279,280. Indeed work from Brian Baker has led to ways to incorporate structure guided design to 
tune TCR affinity as well as enhance specificity independent of affinity128,276. In the latter study128, positive 
and negative design was utilized, to our knowledge, for the first time to rationally modify TCR specificity 
and deliberately eliminate cross-recognition to non-target epitopes.  
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The interaction of TCR with peptide/MHC complexes, as well as CD4, CD8 co-receptors presents an 
additional opportunity to modify these complexes to enhance activity, independently of the TCR. Altering 
MHC anchor residues by generating heteroclitic peptide modification has been used as a common strategy 
to modulate immunogenicity in vivo281–283. Recent studies using CD4 yeast display libraries have identified 
highly conserved amino acid residues (glutamine at position 40 and threonine at position 45) which are 
essential for controlling interaction of CD4 with MHCII284. Mutation of these residues to tyrosine and 
tryptophan respectively, is capable of increasing responsiveness of low affinity TCRs to peptide-MHC 
(pMHC) complex. Importantly, these high affinity CD4 mutants appear to elicit increased reactivity to 
MHCII, resulting in stabilization of the pMHC-TCR complex to specifically increase responsiveness to 
cognate antigen and not non-specific antigen responses285. In light of this, it may also be possible to increase 
TCR activity by manipulating amino acids in the globular heads CD8αβ, or increasing binding avidity to 
MHC via glycan engineering of CD8 co-receptor stalks to generate high affinity variants; as high affinity 
CD8 coreceptors which lack these sugar residues are present naturally in double positive thymocytes286,287. 
While many of these techniques appear to be promising ways to enhance TCR sensitivity in vitro, they 
highlight the need to test ways to control activity in living organisms. Recent work from the Irvine group 
shows a biomaterial based delivery system that links IL-15 super-agonist laden nanocarriers to surface 
receptors of CD45, to selectively promote T cell expansion and tumor clearance by mouse T cells and 
human CAR-T cell therapy288.  
 
While the ability to heighten responsiveness of immune receptors is gaining traction, it remains equally 
important to maintain capacity to dampen or shut down engineered immune responses. Sophisticated drug 
controllable synthetic systems present themselves as an alluring, untapped means to modify immune 
receptor activity in vivo. Two competing methods relying upon drug controllable NS3 proteases have 
recently been described to reversibly control transcription factors, transmembrane signaling proteins, and 
drug stabilized variants of dCas9289,290. The ability to control protein activity with these hepatitis C virus 
protease inhibitors will undoubtedly have direct utility in the immunotherapy world. As engineered adaptive 
immune cell therapies gain more traction, it becomes increasingly important to begin developing ways to 
generate transcriptional control of engineered cellular therapeutics in vivo. Specifically, this means 
maximizing sensitivity to target ligands, improving therapeutic responsiveness, incorporating self-
destructible kill switches, and control of master regulatory transcriptional factors in T and B cell lineage 
commitment. Benchmarks to efficiently control immune cells in vivo are further outlined in Fig. 1. 
 
De novo design of immune receptor sequences  
Alongside the idea of developing predictive tools for identifying high-affinity immune receptors and 
epitopes, is the notion that biological evolution can be co-opted to accelerate the pace of identifying orphan 
receptors for desired cognate ligands. Directed evolution of epitopes has widely been explored as a way to 
accomplish this goal. Often this is performed by means of saturation mutagenesis and affinity maturation 
either in vitro or in vivo291–295. Typically applied through phage or yeast display libraries, these approaches 
have been limited in their ability to display largely diverse mammalian antibody libraries or, in the case of 
MHC, require random mutational trial and error in order to be displayed on the surface. One simple and 
versatile strategy employing site-directed mutagenesis utilizes the concept of CRISPR/Cas9-mediated 
homology repair to incorporate degenerate single-stranded oligonucleotides in murine variable heavy chain 
CDR3 to generate large libraries (>105) without the need for plasmid expression vectors, or PCR 
mutagenesis270,296. While libraries generated through homology-directed mutagenesis (HDM) are still 
several orders of magnitude lower than what can be routinely achieved with phage and yeast display 
systems, the system importantly demonstrates its ease of performing deep mutational scanning (DMS)297,298. 
In a similar approach to DMS, directed mutagenesis has also been directly applied to emulate an in vitro 
affinity maturation process in low affinity naive B cell repertoires299. DMS, HDM, or similar in vitro affinity 
maturation processes show the potential of providing meaningful insights to relate antibody function to 
sequence and may be capable of optimizing affinity and specificity of mammalian antibodies and TCRs. 
Although promising, it is important to recognize that these approaches should all be paired with cross 
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reactivity screening to eliminate potentially autoreactive clones, similar to affinity maturation limitations 
imposed by central and peripheral tolerance. 
 
To control for artificial positive and negative selection, methods leading to the generation of secondary 
lymphoid organoid complexes, which emulate artificial thymic and germinal center development, may be 
co-opted as powerful tools to direct evolution of immune epitopes. Artificial thymic organoid (ATO), 
described by Seet and colleagues, demonstrate a robust 3D system capable of generating mature naive 
antigen specific T cells through in vitro differentiation and positive selection of T cells291. T cells used in 
ATO system can also be generated from hematopoietic stem cells obtained from clinically relevant patient 
bone marrow biopsies, highlighting the potential for this system to be used alongside development of 
engineered T cell therapies. Similarly, immune engineered organoids for the generation of 
immunoglobulins have also been developed to further understanding of B cell physiology, malignancy 
development, and immunotherapeutic screening tools300,301. These artificial secondary follicles can be 
generated with tunable control over immunoglobulin class-switching but require starting with digested 
lymphoid tissue (rather than HSC) obtained from a patient’s bone marrow. Artificial secondary lymphoid 
organoid systems have primarily shown their ability to emulate human T- and B-cell selection and 
maturation and play an important role in bridging developmental questions for in vitro and in vivo models. 
Future iterations of these immune organoids also open up the potential for more advanced systems to 
control, manipulate, and artificially focus human immune repertoires to accelerate the development of 
personalized immunotherapies.   
 
Synthetic constructs such as bispecific antibodies215, CAR-T cells and protein scaffold antibody mimetics 
(ex: DARPin, Avimer, AdNectin, Anticalin)302,303 are major innovations in the development of de novo 
design of immunological variables. The synthetic design of these constructs has allowed them to 
compensate for natural failures of the immune system and have begun closing the gap between translating 
promising repertoire sequences, to clinically approved therapeutics. While development of engineered 
therapeutic systems like these are logical end states of de novo design of antibodies, their design, 
validation304 and limitations is beyond the scope of this review. Moreover other reviews have already 
covered Antibody fragments215, Bi-Specific antibodies215, nanobodies305, protein scaffold antibody 
mimetics302,303, heterodimeric chimeric receptors (HCR T)306–308, and CAR-T therapies309,310, which we 
point the reader to. 
 
Beyond immunological and molecular understanding of immune receptor binding, large-scale antigen-
receptor-antigen data may enable computational and machine-learning guided design of epitope and 
paratope sequences88,311–316. Computational design of antibodies aims to create new antibodies with 
biological activity at a much higher rate than traditional methods for antibody discovery, such as animal 
immunization and large-scale library screening. Here, we briefly outline three advancement in antibody 
design, all with different purposes and effects. 
 
The Fleishman lab has recently developed guidelines for the computational design of antibodies based on 
the design of naturally occurring antibodies315,317. They developed an algorithm that uses information on 
backbone conformations and sequence-conservation patterns observed in natural antibodies to design new 
antibody binders. Importantly, the designed antibodies were very different in sequence from natural ones 
but had appropriate affinity and stability. Furthermore, they found that two types of modeling constraints 
were required to make stable and expressible antibodies: conformation-specific sequence constraints as 
well as the use of large backbone fragments that included CDR 1 and 2 simplify sequence and conformation 
space. 
 
The Ofran lab has recently succeeded in the computational design of epitope-specific antibodies. With an 
approach that does not rely on a solved structure of the target, they implemented a computational approach 
that integrates statistical analysis with multiple structural models as well as a random forest classifier to 
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predict specific residue-residue contacts313. For an overview of recent approaches to computational 
antibody design, please refer to Ref313 (Table 1).  
 
Finally, computational antibody design is not only about target specificity and affinity. For therapeutic use, 
developability of antibodies is of equal importance. Current problems in developability are summarized by 
Raybould and colleagues and include high levels of hydrophobicity and  patches of positive and negative 
charge318,319. They derived guideline values for five metrics thought to be important for antibody 
developability based on values seen in post-phase-I clinical-stage (CST) antibody therapeutics: (1) the total 
length of CDRs, (2,3) the extent and magnitude of surface hydrophobicity, (4) positive charge and negative 
charge in the CDRs,  and (5) asymmetry in the net heavy- and light-chain surface charges318. The work by 
Raybould and colleagues builds on the work by Jain and colleagues who first analyzed the above mentioned 
CST antibodies in a comprehensive analysis of 12 different biophysical assays in common use for 
developability assessment320. 
 
Although there has been significant progress in biology-driven computational antibody design both with 
respect to target specificity and developability, it remains unclear how to reconcile optimization of 
specificity and developability since both entities are located in addition to the Fc region, to a major extent, 
in the CDRs of antibodies. More fundamental work is needed to understand the underlying biophysical 
foundations. Even more disconcerting, efforts are almost exclusively focused on antibody-sequence based 
analyses. However, as Kanyavuz and colleagues have recently pointed out: “structural restrictions of the 
canonical topology of the V region impose limits on the ability of antibodies to encompass the breadth of 
possible target epitopes. Incorporation of uncommon chemical groups (such as carbohydrates, sulfates, 
heme or metal ions), use of proteins or reconfiguration of the topology of the antigen-combining sites by 
conformational isomerism might all compensate for the structural hurdles imposed by different 
antigens.”321. It remains entirely unexplored how to perform antibody design by accounting for all possible 
secondary chemical additions and modifications. It may be that with sufficient amounts of data, the high 
dimensionality of the problem is grasped by machine learning. 
 
Recently, there has been exciting machine-learning driven progress in protein folding and chemistry that is 
also very useful for in-silico immune receptor design. Indeed, deep learning continues to push the 
boundaries of protein design, engineering and biomedicine as summarized recently by Ching and 
colleagues322. Of specific importance for protein design are recently reported deep learning guided directed 
evolution experiments that enabled the discovery of a functional green fluorescent protein with mutations 
in non-trivial positions323 demonstrating that the deep learning model was able to supply the directed 
evolution experiments with previously unseen local maxima in the fitness landscape. A7D, Google’s 
DeepMind deep learning based de novo protein structure predictor, is presently the top performer on 
CASP13 (Critical Assessment of Techniques for Protein Structure Prediction)324,325. Furthermore, 
chemistry is currently leading in terms of productive utilization of machine learning for drug discovery326. 
Segler and colleagues trained a deep neural network on all reactions ever published in organic chemistry 
and showed that the neural network can generate small molecule synthesis routes that are equivalent to 
reported literature routes327. More generally, recurrent neural networks may in principle be used for any 
text, sequence or graph328–330 generating task thus leading, in the future, to not only the generation of single 
sequences but entire adaptive immune repertoires. After all, sequence generation is merely a special case 
of repertoire generation331. However, we wish to note here a fundamental problem for the large-scale 
validation of machine-learning based antibody design332: the low throughput of antibody generation333 (and 
related to that: the issue of antibody standardization334,335). It remains currently unfeasible to produce 
10,000s or 100,000s of different antibodies at large scale for verification of antigen specificity or 
developability (Fig. 1).  
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Closing the data gap between immune receptor sequence and cognate epitope for immune receptor 
and epitope engineering 
One-way library screens have shown to be invaluable biotechnology tools for identifying and interrogating 
TCRs, antibodies and peptides336–338. These brute force search methods designed to identify rare matches 
for a given target are single-target-focused and therefore narrow in their breadth of search for identifying 
matching pairs (binding partners). This identification bottleneck poses a significant challenge to 
pharmaceutical target discovery as well as the creation of large-scale training datasets of known B- and T-
cell receptor sequence pairs for machine learning approaches. Given this limitation, library-on-library 
screens (two-way screens) may prove to be a more desirable biotechnology platform for generating large-
scale datasets of receptor-epitope pairs. Although no specific reports on the development of immune 
receptor library on two-way library screens has been reported, protein-protein interactions by yeast mating 
has recently appeared as a possible platform which could be exploited for these applications339. Using 
synthetic MATa and MATα haploid cells, a high-throughput method to interrogate protein-protein 
interactions was devised. Yeast mating was reprogrammed to link interaction strength with mating 
efficiency by substituting the MATa and cognate MATα sexual agglutinin subunits with barcoded binding 
peptides. In its current form, the approach presents itself as a proof of concept analysis tool capable of 
characterizing 7,000+ distinct protein-protein interactions. Barcoded synthetic agglutination gene cassettes 
present itself as a unique library-on-library selection tool. When combined with machine learning 
approaches, this system could generate training datasets capable of advanced receptor-based 
epitope/antigen prediction with single-epitope and single paratope resolution. Library on library selection 
methods would be the beginning of an entirely new era for the understanding of receptor-antigen pair 
formation. Once in place, we may then be able to detect high-affinity epitopes which may not be able to 
pass positive selection but produce functionally high affinity immune receptors. Importantly, we can then 
also finally begin to understand cross-reactivity and immunodominance340 (extent to which one target 
attracts binders). With the advent of high-throughput library-on-library screening, new insight may enable 
the development of standard protocols for determining cross reactivity, and immunological functional 
outcomes may be predicted from paratope and epitope sequences alone. 
 
Beyond library screens, Eyer and colleagues have recently published a microfluidics approach, called 
DropMap, to measure antigen-specific affinity and secretion rate of 100,000s of antibody secreting cells341. 
If, in the future, coupled with high-throughput BCR and transcriptome sequencing, the relationship between 
receptor sequence and target antigen may be screened at unprecedented scale342. 
 
In the effort to understand the statistical relationships of immune receptor-antigen pairs, several databases 
have been developed that have gathered such information: VDJDB343, Abysis344, IEDB345, ABDB90, 
McPAS-TCR62. These databases are continuously maintained and updated and therefore a valuable resource 
for future machine learning efforts. Superseding these comparatively smaller databases, are major efforts 
such as the iReceptor database7 or the Observed Antibody Space346, in part led by the AIRR Community 
(AIRR: adaptive immune receptor repertoires) to build large-scale databases that gather most sequencing 
datasets published in a preprocessed (AIRR-compliant) format that enables repaid repurposing of publicly 
available data for custom and new data analysis347,348. In fact, it was recently shown by Krawczyk and 
colleagues349 that out of 242 post Phase I antibodies, 16 antibodies with sequence identity equal or higher 
to 95% of both heavy and light chains were also stored in publicly available immune receptor databases. 
While the databases containing immune receptor-antigen pairing are useful for prospective therapeutics 
discovery, entire repertoires will be needed for training machine learning approaches to immune (or disease) 
state prediction.  
 
Challenges in machine learning analysis on immune receptor repertoires 
Machine learning analysis on adaptive immune receptor data may be divided into two distinct problems: 
predicting antigen specificity given a specific receptor sequence and predicting disease states given a 
repertoire of immune receptor sequences. 
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The prediction of antigen specificity for a single receptor can usually be given in the form of a typical binary 
classification problem – whether or not a given receptor sequence is specific to an antigen/epitope of 
interest. There are several options for which receptor regions to consider: it may be the full V(D)J receptor 
sequence or only parts considered most critical for specificity (e.g., CDR3). Furthermore, it may be based 
on a single chain (typically VH or TCRβ) or with recent single cell-based technologies paired VH-VL/TCRβ-
TCRα. Finally, as an alternative to framing this as a problem of classifying antigen specificity based on 
receptor sequence, one can set out to develop joint computational models of paired receptor-epitope data.  
 
Using one-hot encoding, amino acids of the receptor sequence can be considered as distinct categorical 
values and represented as binary vectors. Another option is to translate the receptor sequence to a space of 
physico-chemical properties as performed by Thomas and colleagues350. As the input data is of variable 
length (typically CDR sequence length), it requires padding or alignment. The input data may also be 
represented by k-mers, which are frequency profiles of shorter subsequences (where k quantifies the 
nucleotide or amino acid length of the subsequence).  
 
Intriguingly, the main challenge for machine learning analysis of immune receptors is the low 
dimensionality of the feature space, which is known to distinguish a very large number of antigens. Briefly, 
since antigen specificity is mainly determined by a ≈5–20 amino acid long VH/TCRβ CDR3 sequence, the 
recognition and classification of billions of different antigens is based on decision boundaries within a 
feature space of merely ≈5–20 dimensions (or ~100–400 dimensions after one-hot encoding the categorical 
amino acid values). The low dimensionality implies the presence of strong high-order dependencies 
between amino acids (dimensions), which makes the learning task very difficult (without strong high-order 
dependencies, such a large number of distinct specificities could not be represented in the very limited 
number of dimensions). These strong dependencies reflect that the receptor in reality binds as a 3-
dimensional structure, where variation at any given position may have implications for the entire structure 
and where residues that are distant along the sequence can be close in the folded 3D structure. Indeed, the 
majority of antibody epitopes, for example is thought to be conformational144. 
 
With these high-order dependencies as a premise, a fundamental outstanding challenge for machine 
learning on immune receptors is to determine the smoothness of antigen specificity in sequence space – in 
which ways sequences can change while retaining antigen specificity. This will have major implications 
for the choice of receptor sequence encoding because the main purpose of an encoding is to define a set of 
dimensions (features) that capture smoothness of the desired response variable (antigen specificity). The 
sequence signal associated with a given antigen specificity will likely be distributed among a set of separate 
subspaces of the sequence space, although present knowledge of this is very limited. A useful approach 
forward would be to benchmark351 the performance of alternative models and methods on simulated data 
reflecting different hypothetical forms of sequence signals of antigen specificity.   
 
In terms of smoothness and regularization assumptions, previous work on machine learning of receptor 
sequence specificity can mainly be placed in two categories: 
1) Approaches assuming local smoothness in full-dimensional sequence space. Here, receptors having high 
general sequence similarity (e.g. according to Hamming or edit distance) in a  receptor region such as the 
CDR3 are assumed to share antigen specificity, without any domain-specific consideration of the particular 
sequence discrepancies24,83.  
2) Approaches assuming that antigen specificity results from a combination of components in the form of 
receptor subsequences (contiguous or gapped k-mers), akin to natural language where semantics arise from 
a combination of words according to a given grammar82,91,95,98. In biological terms, one assumes the 
existence of receptor subsequences contributing defined binding characteristics that are not specific to a 
particular complete sequence context for a core region like CDR3. One could assume that components 
(subsequences) have defined binding characteristics independent or dependent of the position within a 
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region like CDR3, which would imply encoding of a receptor sequence by k-mer frequencies or by k-mer-
at-given-position frequencies, respectively. 
 
Note that the use of k-mers does not in itself imply the second assumption. For instance, Glanville and 
colleagues83 classify antigen specificity using in part a distance function based on the full k-mer frequency 
profiles of a pair of sequences. By incorporating the frequency of every k-mer, it is effectively a measure 
of the full sequence similarity, and thus according to the first assumption.  
 
Machine learning is often contrasted to traditional statistics as being guided by general rather than specific 
priors. This means that instead of incorporating specific a priori expert knowledge about the domain, 
machine learning is implicitly guided by regularization priors that are shared by most prediction problems. 
According to such a perspective, different encodings, methods and architectures can be seen as reflecting 
different underlying regularization priors (smoothness assumptions). Comprehending antigen specificity 
smoothness in sequence space and developing well performing machine learning models is thus two facets 
of the same problem – with the first being a useful entry point from the direction of experimental 
immunological research and the second one being from the direction of benchmarking and machine learning 
research. 
 
The prediction of disease states given a repertoire of receptor sequences is at its core a multi-instance, 
multiple-label learning problem. The term multi-instance denotes that the input data consists of a large set 
of receptor sequences, of which only an unknown subset is relevant for a particular disease. The term multi-
label denotes that what is to be predicted is the presence/absence of multiple distinct disease states for each 
repertoire. Although one can always focus on a single disease and frame the problem as a binary 
classification of this disease state, a repertoire will inevitably contain receptors relevant for a variety of 
disease states, where there is no obvious way to filter out receptors not relevant for a single considered 
disease. Additionally, it is of importance that a learnt discriminator is representing the intended disease 
state rather than confounding factors (such as the age or the genetic or environmental background of the 
patients from whom the data were obtained). Both the multi-instance and multi-label characteristics 
contribute complexity to the prediction problem352. Furthermore, all challenges discussed for machine 
learning on individual receptors essentially carry over to the repertoire setting.  
 
An outstanding challenge for prediction of disease states of repertoires is to integrate aspects of antigen 
specificity and V(D)J recombination probability. A fundamental assumption underlying machine learning 
approaches is that antigen specificity contributes selection pressure to a repertoire, allowing antigen-
specific receptors to be detected through analysis of sequence or motif enrichment. However, rather than 
operating on a uniform sequence background, this selection pressure operates on the highly uneven 
sequence generation probabilities of V(D)J recombination. A fundamental challenge is thus to delineate 
sequence enrichment due to underlying generation probability versus antigen-based selective pressure. 
Such delineation would allow much more accurate estimates of the strength of selective pressure operating 
on a given sequence (motif). Furthermore, since the germline affects V(D)J recombination probability, the 
sequence generation probability could function as a mediator for confounding factors associated with a 
group of donors defined based on a trait of interest. Controlling for sequence generation probability could 
thus allow to break the connection to germline-associated factors, allowing both accurate and non-
confounded estimates of antigen-based selective pressures. 
 
While the discovery of antigen-associated patterns in receptor sequence is a relatively new field, the 
discovery of patterns in biological sequences in general has long roots more than forty years ago353. The 
discovery of sequence motifs representing DNA regulatory elements354 has clear similarities to the 
discovery of receptor motifs, with the main difference being that regulatory element patterns are of lower 
complexity and typically embedded in longer sequences. It could be particularly relevant to draw inspiration 
from how the DNA motif field explored the difficulty of the problem and the performance of proposed 
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methods. A very appealing approach is the one taken by Tompa and colleagues355, where the authors of 
several competing methods came together to benchmark their methods on a collection of experimental 
datasets. However, due to the high variability of method performance across datasets and the limited total 
size of available data, the authors were not able to draw clear conclusions. Keich and colleagues356 followed 
an alternative perspective, where they instead sought to inform on the problem from the theoretical side by 
delineating how subtle patterns could be before becoming indistinguishable from background. A hybrid 
perspective was employed by Sandve and colleagues357, where a benchmark suite was created by assigning 
experimental datasets to three distinct groups according to an assessment of pattern complexity and Bayes 
error. The receptor bioinformatics field faces many of the same challenges, related to undetermined pattern 
characteristics, undetermined signal strength and limited availability of ground truth datasets. The field 
could thus get a head start by systematically building upon the experiences made in the field of regulatory 
element patterns.  
Once a machine learning model has been decided on, it is crucial, especially in biomedical applications, to 
be able to interpret the results and the reasoning behind them358. In contrast to simple, linear models, the 
reasoning is not straightforward for more complex models or deep learning. Lanchantin and colleagues 
attempted to understand machine learning results by highlighting data which influences the decision the 
most359 and Quang and Xie described a method that map the learned values to standard representations360. 
Furthermore, there exist software packages available which aim to extract the most significant features (see 
Focus Box 1). In the case of immune repertoires, the retrieval of such features would reveal the patterns 
characterizing the disease or antigen-binding and provide further insights for diagnostics and drug 
development. How to extract disease and antigen-specific motifs from immune receptor data remains 
largely unresolved. 
In summary, given the complex nature of immune receptor repertoires, it may be of importance to integrate 
both sequence and frequency information as well as network similarity and phylogenetics frameworks361,362 
into future machine learning architectures in an effort to improve signal detection and decrease the influence 
of bystander noise. 
Relating immune receptor antigen specificity to cellular transcriptomic profile  
Currently, there exist very few studies that have linked immune receptor sequence and transcriptome to 
antigenic site specificity. Given that the transcriptome can be linked to cellular dynamics, linking the 
transcriptome with antigen specificity is important for understanding variation of antigen specificity on the 
cell subset level and cross-organ level. Specifically, it remains unknown how transcriptional programming 
correlates with epitope specificity across developmental stages, organ locations and disease states (health, 
cancer autoimmunity, infection). Indeed findings by a recent study on intratumoral T cells (breast cancer) 
suggests that T-cell phenotypes are likely shaped by a combination of antigenic TCR stimulation and 
environmental stimuli363. If transcriptome and antigen specificity are causally linked, then it may be 
conceivable to engineer higher affinity clones not by direct changing of the immune receptor but by 
changing key regulatory pathways, for example.  
 
A crucial step in relating sequence to function is integrating transcriptomics with sequence chain pairing. 
The ability to subgroup and classify cells based on expression profile and paired antigen receptor 
information is an essential data factor for the mining of acumen and meaningful patterns in immune receptor 
sequences. While examples of integrating transcriptomics and chain pairing may be found in commercial 
systems such as that of the 10xGenomics platform, and other single-cell emulsion based assays, they are 
troubled by sequence read depth complications364. Lymphocytes appear to have low levels of mRNA 
transcripts of their heavy and light  chains, and contain approximately 100 mRNA transcripts per adult B 
cell365. Furthermore, individual cells often lack consistency in sequencing depth364,366, which is needed to 
accurately discriminate common markers (CD4, CD8, CD44, B220, CD62L etc.) to group receptors on a 
population level367. Development of high throughput screening assays capable of retaining chain-pairing 
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and transcriptomic information will be a crucial next step to dissecting antigen receptor sequence and the 
functional outcomes of the cells. Such an assay could link disease specific effector cells to receptor epitope 
and would likely provide crucial insights into peptide specific motifs and predicting function from amino 
acid sequence.  
 
Over the past few years, in addition to the 10xGenomics platform, there have been a few papers reporting 
computational tools that can extract immune receptor information from RNA-seq data368–374 and applied to 
T-cell fate mapping in Salmonella infection368 or relating clonal expansion to T-cell exhaustion state375. 
Taken together, linking transcriptome and immune receptor specificity is important to link molecular and 
cellular immune cell components for improved understanding of the microevolutionary processes that 
govern antigen-specific adaptive immunity.  
Conclusion 
Since its inception nearly a decade ago34,35, the quantitative analysis of immune receptor repertoires has 
enabled deep insight into the molecular basis of adaptive immunity. Many challenges remain to be 
addressed on each aspect of the investigation of immune repertoires to enable predictive immune receptor 
repertoire engineering and analysis: biotechnology, genomics, proteomics and computational immunology, 
machine learning and pattern mining. These challenges revolve around the one major knowledge gap of 
current research: the lack of insight into the immunological function and specificity of each immune 
receptor. Billions of immune receptor sequences stored in public databases are virtually useless for 
biomedical research if their specificity remains unknown. This knowledge gap pervades most current 
repertoire studies leaving behind, regardless of the study size, a hint of immunological inconclusiveness. 
Increasing our knowledge of the immune receptor’s function will provide a gold standard and ground truth 
data for in silico diagnostics and therapeutics discovery. As both the public as well as funding agencies are 
invested in the design and analysis of real-world data, separation of noise from immunological signal will 
even more so rely on detailed understanding of the immune receptor-antigen interaction map, the immune 
grammar. Once resolved and amplified with next-generation computational immunology and machine 
learning, the possibilities for a multidimensional understanding and application of adaptive immunity will 
hopefully transcend our current imagination.  
 
Finally, while we hope to have shown the great potential quantitative immunoengineering solutions harbor 
for the advancement of immunology, biomedicine and (digital) immunobiotechnology, we would like to 
caution against the ongoing separation of basic [experimental and computational] immunology and 
immunoengineering. In a recent opinion article for PNAS on “Why science needs philosophy”, Thomas 
Pradeu and colleagues cited the late Carl Woese376: “a society that permits biology to become an 
engineering discipline, that allows science to slip into the role of changing the living world without trying 
to understand it, is a danger to itself.”377. Indeed, only when merging fundamental immunology and 
immunoengineering, we may be able to understand, recreate, repair and improve adaptive immunity in a 
rule-driven fashion. 
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Focus Boxes 
 
Focus Box 1: Brief summary of deep learning and its architectures. 
A prominent class of machine learning algorithm is artificial neural networks (ANN)405. Typical ANNs 
comprise an input layer, a single or several hidden layer(s), and an output layer. Each layer comprises a set 
of nodes; nodes comprising hidden layers are termed hidden nodes. Theoretical studies on the 
approximative capabilities of these networks have shown that even a network with a single hidden layer 
may function as a universal approximator406,407 (a function that maps any input to any output with 
sufficiently accurate approximation), albeit, with enough hidden nodes.     
 
A neural net that has only a single hidden layer is known as ‘shallow’. Early networks, for instance a 
multilayer perceptron or feedforward neural network408, were setup in such a way that the set of nodes in 
the input layer is connected to the set of nodes in a single hidden layer. Finally, the hidden layer is connected 
to the output layer. Computationally, the ‘connection’ is made by a parameter weight. Intuitively, inputs 
are transformed (weighted) by the hidden layer to produce the outputs.  
 
A more complex network comprising several hidden layers is referred to as ‘deep’ network. In biomedical 
applications as well as chemistry, deep neural networks have seen great success recently ranging from the 
prediction of transcription factor binding409, skin cancer410 and entire conception of chemical synthesis 
pathways327. Networks of this type may also include different types of hidden layers/nodes411–413. Recently, 
‘very deep’ architectures (16 layers or more) demonstrated superior performance  to their deep counterparts 
on a set of benchmarking image recognition datasets414,415. However, going deeper may not be the only 
solution in the quest for optimal performance416,417.  
 
Both shallow and (very) deep networks learn the weights from the input data, for deep networks this process 
is termed deep learning. Opportunities and challenges on applying deep learning in biology and medical 
research have been described in length elsewhere322. As of yet, it remains unclear as to exactly why deep 
learning is so successful in classification, prediction and generation. Ongoing research suggests that deep 
neural networks are especially adept at amplifying class-specific signal and ignoring class-unspecific 
noise94, however, mechanistic details on what to amplify or ignore are obscured by the complexity of their 
architecture akin to a black box. Efforts to deconvolute deep and very deep networks (turning the black box 
into a glass box) have gained momentum in recent years, tools and techniques such as Integrated Gradients, 
LIME, and human-in-the-loop418–420 are all geared towards attributing the prediction of a deep network back 
to its inputs.    
 
Focus Box 2: Recognition holes in the immune repertoire 
Holes in the immune repertoire were first hypothesized in 1971, and were initially thought to appear because 
of an inability of lymphocyte receptor gene mutations to generate target specificity421. As 
immunoengineering edges closer to de novo design of antibodies and TCR, it becomes increasingly 
important to understand where the natural boundaries of the immune repertoire lay, and their purpose. 
Incorporation of a model which predicts off limit V(D)J recombination could assist in developing 
engineered immune receptors with minimized cross reactivity. Concurrently, recognition holes may 
represent a beneficial target for immunoengineering by allowing the generation of rare pathogen 
neutralizing antibodies which are normally eliminated via central or peripheral tolerance. 
 
Perelson and Oster asked how large a repertoire needs to be in order to be complete (no large holes in the 
repertoire). Specifically, they formulated the problem as follows: “given a set of n distinct, randomly made 
receptors, what is the probability that a randomly encountered antigen is recognized by at least one of the 
receptors?” To approach this problem, they introduced the concept of shape space422. Briefly, a receptor’s 
shape is defined by the constellation of features important in determining binding to the antigenic space. A 
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point in an n-dimensional space, ‘‘shape space’’ S, specifies the generalized shape of a receptor binding 
region. The shape space is a bounded region with volume V, assuming a restricted range of widths, lengths, 
charges, etc. that a receptor combining site can adopt. Complementarily, epitopes are also characterized by 
generalized shapes, which should lie within V. Because each receptor can recognize all antigenic 
determinants within a recognition ball, a finite number of antibodies may recognize a nearly infinite number 
of antigens thus giving a possible theoretical explanation of the broad recognition capacity. Specifically, 
Perelson and colleagues determined that a repertoire of 106 randomly created receptors equates to 0.01% of 
escape epitopes. A caveat is however that these calculations were performed prior to the advent of high-
throughput sequencing which has shown unequivocally that the immune repertoire is not created in a 
uniformly distributed fashion (let alone the predetermination imposed by the restricted germline gene 
repertoire)3. While the concept of the shape space has been instrumental in investigating repertoire holes, 
its main limitation is that it cannot be used for modeling of cross-reactivity, which is one of the main features 
of the adaptive immune system to increase its recognition breadth239,423. More recent mathematical 
approaches allow readily for the simulation of cross-reactivity121,321,424,425 (see Section on Mathematical 
modeling of immune receptor recognition). 
 
Central and peripheral tolerance appear to play a major role in the development of “recognition holes” 
across the development of the immune repertoire. Several studies have shown that a majority of immature 
human and mouse B cells generate autoreactive antibodies which are later eliminated through receptor 
editing426,427. Moreover, approximately 40% of antigen experienced IgG class switched antibodies from 
healthy human donors were also shown to have autoreactivity428. TCR repertoire depletion additionally 
occurs during thymic selection, whereby CD8+ TCR repertoire size is inversely related to individual MHC 
diversity, causing an apparent tradeoff between MHC diversity and TCR repertoire size101,429. It is not 
known whether recognition holes exist entirely due to the presence of central and peripheral tolerance, or 
if specific amino acid combinations (sequence motifs) are capable of naturally evading immune monitoring. 
In TCR recognition, holes have appeared to be associated with human aging. Specifically, it appears that 
age associated decline in naive CD8 T cell diversity, may cause naturally low frequency precursors to 
become completely absent. This was shown to result in repertoire holes which compromise the ability to 
generate protective immunity105,430. HIV provides another interesting instance of where we believe holes in 
the repertoire exist alongside autoreactive antibodies. While broadly neutralizing human monoclonal 
antibodies (BnAbs) to HIV do exist, they are exceedingly rare. Many of these BnAbs have been found to 
have autoreactive properties in vitro431. In fact, it has become apparent that BnAbs to HIV often overlap 
with autoreactivity, and are disproportionately generated in patients with autoimmune diseases causing 
defective tolerance432. One report suggests that directed breaches in peripheral tolerance can naturally 
promote generation of these neutralizing HIV antibodies433. 
 
Moreover, approximately 8% of the genome is known to be composed of endogenous sequences with a 
high degree of similarity to infectious retroviruses434. Could it be that viruses partially exploit recognition 
holes generated by central and peripheral tolerance through becoming self over time? While this may be a 
potential consequence of tolerance, enormous holes in the recognition repertoire are actually more a feature 
rather than a bug of the immune system. Repertoire holes may provide essential checks on the development 
of autoimmune disease, and paradoxically can sometimes enhance protective antibody responses to foreign 
immunogens435. Given that recognition holes show correspondence to autoreactive epitopes which have 
overlap with pathogens, we wonder: Are there immunological settings that can selectively control tolerance 
to allow for the generation of BnAbs against specific pathogens? Future immunoengineering may seek to 
orchestrate breaches of self-tolerance in order to manipulate and expose potentially valuable “hidden 
epitopes”. 
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Table 1: Summary of the most frequently used single-cell sequencing methods. 
Method name Target Single-cell 
technology 
UMI use Throughput* 
Smart-seq378 
Smart-seq2379 
Transcriptome Micropipetting, 
FACS 
No Low 
SMART-Seq 
v4/Fluidigm C1 
Transcriptome Microfluidics Yes Low  
MARS-seq380 Transcriptome FACS Yes Low 
Microwell-seq381 Transcriptome Microwells Yes Medium 
CytoSeq382 Transcriptome Microwells Yes Medium 
pairSEQ383  TCR Microwells Yes High 
Drop-seq366 Transcriptome Microfluidics Yes High 
10x SC384 Transcriptome, 
TCR/BCR 
Microfluidics Yes Medium 
DeKosky (2013)385 BCR Microwells No Medium 
DeKosky (2015)207 BCR Microfluidics No High 
Briggs209 Transcriptome, 
TCR/BCR 
Microfluidics Yes High 
SPLiT-seq210 Transcriptome Combinatorial 
barcoding 
Yes High 
sci-RNA-seq386 Transcriptome Combinatorial 
barcoding 
Yes Medium 
Devulpally387 BCR Manual pipetting No High 
Busse388 BCR Combinatorial 
barcoding 
Yes Medium 
CEL-Seq389 
CEL-Seq2390 
Transcriptome Micropipetting 
Microfluidics 
Yes 
Yes 
Low 
Low 
STRT-seq391 
STRT-seq2i392 
Transcriptome 
Transcriptome 
FACS 
FACS 
No 
Yes 
Low 
Low 
scCAT-seq393 Transcriptome, 
epigenome 
FACS No 
Yes 
Low 
Zong394 Genome Tissue lysis No Low 
Xu395 Exome Micropipetting No Low 
scRRBS396 
Q-RRBS397 
Methylome 
Methylome 
Micropipetting 
Micropipetting 
No 
Yes 
Low  
Low 
snmC-seq398 
snmC-seq2399 
Methylome FACS No Low 
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scATAC-seq400 Epigenome Microfluidics Yes Low 
scBS-Seq401 Methylome FACS No Low 
scWGBS402 Methylome FACS No Low 
scM&T-seq403 Methylome, 
Transcriptome 
FACS No Low 
scTrio-seq404 Methylome, 
Transcriptome, 
Genome 
Micropipetting No 
Yes 
No 
Low 
TetTCR-seq224 TCR FACS Yes Low 
*Legend: Low: <10 000 cells per experimental run, Medium: 10 000–100 000 cells per experimental run, 
High: > 100 000 cells per experimental run 
 
 
Fig. 1: Key advances and outstanding challenges in quantitative engineering and analysis of adaptive immune receptor 
repertoires. The immune system recognizes and neutralizes threats by evolving its sensors, B- and T-cell receptors, into a robust 
repertoire that is specific and at the same time broadly reactive. This is a highly potent system, but not without flaws. Pathogens 
sometimes slip through the cracks and an over- or under-reactive immune system manifests itself in the form of cancer or auto-
inflammatory immune diseases. Recent advancements in both scale and sophistication of experimental and computational 
techniques have allowed experimental and digital immunoengineers to not only probe more complex questions, but importantly, it 
has ushered the era of augmented immunity. For the first time, the combination of ultra-large data and intelligent computational 
solutions opens a possibility to repair, recreate, and improve the immune system quantitatively and with great precision. Notable 
recent advancements such as the development of chimeric antigen receptor (CAR T cells) has indeed propelled the field forward 
considerably. However, a number of outstanding challenges remains to be overcome. Here we summarize the key advances in 
genomics, proteomics, computational immunology, and biotechnology along with some of the challenges. BCR and TCR molecular 
graphics were generated using UCSF ChimeraX436. 
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